Role of molecular analysis in the adjuvant treatment of gastrointestinal stromal tumours: It is time to define it  

作　　者：Margherita Nannini Maria A Pantaleo Guido Biasco 

机构地区：[1]Department of Hematology and Oncological Sciences "LA Seràgnoli", Sant'Orsola-Malpighi Hospital, University of Bologna [2]"Giorgio Prodi" Cancer Research Center, University of Bologna

出　　处：《World Journal of Gastroenterology》2013年第16期2583-2586,共4页世界胃肠病学杂志（英文版）

摘　　要：Sendur et al pointed out the attention on the importance of mutational analysis for adjuvant treatment of gastrointestinal stromal tumor (GIST) in an article published in World Journal of Gastroenterology . In particular, they suggested that the optimal dose and duration of adjuvant therapy could be defined by the mutational status of the primary disease. This comment would underline the importance of centralised laboratories, given the increasingly important role of molecular analysis in the work-flow of all GIST, and the need of retrospective analyses for subgroups population stratified for the mutational status from the available studies in the adjuvant setting, in order to define the role of mutational analysis in choosing the optimal dose and duration of adjuvant therapy.Sendur et al pointed out the attention on the importance of mutational analysis for adjuvant treatment of gastrointestinal stromal tumor (GIST) in an article published in World Journal of Gastroenterology. In particular, they suggested that the optimal dose and duration of adjuvant therapy could be defined by the mutational status of the primary disease. This comment would underline the importance of centralised laboratories, given the increasingly important role of molecular analysis in the work-flow of all GIST, and the need of retrospective analyses for subgroups population stratified for the mutational status from the available studies in the adjuvant setting, in order to define the role of mutational analysis in choosing the optimal dose and duration of adjuvant therapy.

关 键 词：GASTROINTESTINAL STROMAL tumours Plateletderived growth factor receptor alpha KIT WILD-TYPE Molecular analysis IMATINIB ADJUVANT treatment 

分 类 号：R735[医药卫生—肿瘤]